1.Self-Reporting Molecular Prodrug for In Situ Quantitative Sensing of Drug Release by Ratiometric Photoacoustic Imaging.Wang, S.; Fu, Q.; Su, L.; Wu, Y.; Zhu, K.; Yang, D.-C.; Yang, X.-Z.; Weng, X.-L.;Liu, J.-Y.*; Song, J.*ACS Sensors, 2023, 8, 4737-4746.
2.A promising strategy for synergistic cancer therapy by integrating a photosensitizer into a hypoxia-activated prodrug.Yang, D.-C.; Yang, X.-Z.; Luo, C.-M.; Wen, L.-F.;Liu, J.-Y.*; Lin, Z.European Journal of Medicinal Chemistry,2022,243, 114749.
3.A Hypoxia-Activated Prodrug Conjugated with a BODIPY-Based Photothermal Agent for Imaging-Guided Chemo-Photothermal Combination Therapy.Yang, D.-C.; Wen, L.-F.; Du, L.; Luo, C.-M.; Lu, Z.-Y.;Liu, J.-Y.*; Lin, Z.*ACS Applied Materials & Interfaces,2022,14, 40546-40558.
4.Hypoxia-activated prodrug combining site-specific chemotherapy and light-driven photothermal therapy.Weng, X.-L.; Luo, C.-M.; Gao, T.-J.; Yang, X.-Z.; Liu, Q.*;Liu, J.-Y.*Sensors and Actuators: B. Chemical, 2024, 415, 135976.
5.Multifunctional organic nanomaterials with ultra-high photothermal conversion efficiency for photothermal therapy and inhibition of cancer metastasis.Yang, X.-Z.; Wen, L.-F.; Xu, G.; Lin, H.-H.; Wang, S.;Liu, J.-Y.*Bioorganic Chemistry, 2023, 130, 106220.